Semaglutide Dosage for Weight Loss

Semaglutide for weight loss is prescribed at a target dose of 2.4 mg injected once weekly, but reaching that dose takes about four months of gradual increases. The escalation schedule matters as much as the final number: starting low and stepping up monthly keeps side effects manageable while the body adjusts. In the pivotal trial that led to FDA approval, people who reached and stayed on the 2.4 mg dose lost roughly 15% of their body weight over about 16 months, a result that changed the landscape of obesity treatment. But the path from the starting dose to the maintenance dose, and what happens along the way, shapes real-world outcomes more than most people expect.

The Standard Dose Escalation Schedule

The approved injectable semaglutide for weight loss (branded as Wegovy) follows a fixed five-step escalation. You start at 0.25 mg once weekly for four weeks, then move to 0.5 mg for four weeks, then 1 mg for four weeks, then 1.7 mg for four weeks, and finally arrive at the 2.4 mg maintenance dose. Each step up gives your gastrointestinal system time to adjust, because semaglutide slows stomach emptying and acts on brain regions that regulate appetite, and both of those effects can cause nausea when the dose increases suddenly.

This 16-week ramp-up is not optional guidance; it is part of the approved prescribing protocol. The reason is practical: semaglutide works by mimicking a hormone called GLP-1 that your gut naturally releases after eating. The drug activates GLP-1 receptors in brain areas involved in hunger signaling, meal termination, and food reward, which together reduce appetite, curb cravings, and lower how much energy you take in at each meal.¹ Hitting those receptors too hard too fast is what makes people feel nauseated, so the escalation gives the system time to adapt.

Semaglutide is indicated for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.² The same 2.4 mg target dose applies across those groups. Dose adjustments are not required for mild or moderate kidney or liver impairment, though monitoring is recommended for people with severe impairment.³ Studies of semaglutide in people with hepatic impairment found that drug exposure was not meaningfully changed, supporting the idea that dose adjustment is not necessary in that population.⁴

How Much Weight People Actually Lose

The headline number from the landmark STEP 1 trial: people on 2.4 mg semaglutide weekly lost an average of about 15% of their body weight over 68 weeks, compared with about 2.4% in the placebo group. That works out to an average loss of roughly 15 kg (about 33 pounds). More than half of participants lost 15% or more of their starting weight, and about seven in ten lost at least 10%.⁵ In a separate trial focused on people with obesity and prediabetes, semaglutide 2.4 mg produced about 14% weight loss at one year, along with higher rates of reversion to normal blood sugar.⁶

These trial results represent best-case scenarios, where participants followed a structured lifestyle program and had regular check-ins. Real-world numbers are somewhat lower, mostly because people do not always stay on the medication or follow the titration schedule precisely. In one real-world cohort from an integrated health system, patients who remained on treatment for a full year lost about 14% of their baseline weight, while those who dropped off early averaged about 6%.⁷ Another study from an academic obesity clinic found a median weight loss of about 14% in patients who persisted on treatment for 12 months or more.⁸ The message is consistent: sticking with the medication at the target dose tracks closely with the trial results, but the gap widens quickly when adherence falters.

Why Following the Titration Schedule Matters

A surprising number of people deviate from the recommended monthly dose-escalation schedule. One analysis of commercially insured adults found that most users had strayed from the planned escalation within the first five months. By month five, nearly half had discontinued entirely, and higher out-of-pocket costs were strongly linked to higher dropout rates.⁹ In real-world data from a Medicaid population, about 60% of members were still persistent with their GLP-1 medication at six months.¹⁰

Titration fidelity directly affects outcomes. Patients who closely followed the approved escalation schedule achieved about 12.5% weight loss at 12 months, nearly double the 7.2% seen in patients who used other titration patterns.¹¹ The implication for anyone starting semaglutide is straightforward: resist the urge to skip steps or stall at a lower dose out of caution. The escalation is designed to get you to 2.4 mg in 16 weeks, and deviating from it tends to mean less weight loss, not fewer side effects.

Some people do stay at a lower dose because the side effects at 1.7 mg or 2.4 mg are intolerable for them. That is a conversation to have with a prescriber. In the academic obesity clinic study, only about 23% of semaglutide users escalated all the way to the 2.4 mg dose, while 81% reached at least 1 mg.¹² Staying at a moderate dose still produces meaningful weight loss, just less of it, and for many people that tradeoff is reasonable.

Side Effects and Their Relationship to Dosing

Gastrointestinal symptoms are by far the most common side effects, and they cluster heavily around the dose-escalation period. Nausea, vomiting, diarrhea, and constipation are the usual complaints. In clinical trials, the vast majority of these events were mild to moderate (about 98% of them), not serious (over 99%), and transient, typically peaking during or shortly after each dose increase.¹³ Most people find the nausea improves once they have been at a stable dose for a few weeks.

There is a persistent idea online that the nausea is what causes the weight loss, as if semaglutide is just making you feel too sick to eat. The data do not support this. The appetite-reducing effects are driven by the drug’s action in the brain, where it activates GLP-1 receptors in the hypothalamus and brainstem to reduce hunger, improve control over eating, and blunt food cravings, particularly for savory and fatty foods.¹⁴ People who experience no nausea at all still lose clinically meaningful weight on the medication.

Oral Semaglutide Dosing

Semaglutide also comes as a daily pill, which is a different beast from the weekly injection. The original oral formulation was approved for type 2 diabetes at doses of 3 mg, 7 mg, and 14 mg daily. For diabetes management, oral semaglutide at 14 mg daily produced modest weight loss compared with other diabetes drugs, losing a couple of extra kilograms over a year relative to the comparator.¹⁵ That is helpful if you have diabetes, but it was not competitive with the injectable 2.4 mg dose for pure weight management.

A higher oral dose has changed this picture. A trial of oral semaglutide at 25 mg daily for weight loss showed about 13.6% weight loss over 64 weeks, compared with 2.2% with placebo, bringing it within range of the injectable formulation’s results.¹⁶ The tradeoff is higher rates of gastrointestinal side effects (about 74% of participants reported them, versus 42% on placebo), and the oral version requires specific dosing conditions: you take it on an empty stomach with no more than 4 ounces of plain water and then wait at least 30 minutes before eating, drinking, or taking other medications. This is because the absorption enhancer in the tablet is easily disrupted by food and other liquids.

Real-world data on the existing oral formulations (at 14 mg daily, not the newer 25 mg dose) have been more modest, with completers losing about 5.7% of body weight after a year.¹⁷ The gap between those numbers and the injection is real and worth knowing about if you are weighing options.

What Happens When You Stop

Weight regain after stopping semaglutide is substantial and well documented. In the extension of the STEP 1 trial, participants who discontinued the drug after 68 weeks of treatment regained about two-thirds of the weight they had lost within the following year. Net weight loss from the start of the study to one year post-discontinuation was only about 5.6%, down from the roughly 15% achieved on treatment. Improvements in blood pressure, cholesterol, and blood sugar that had occurred during treatment also reverted toward their starting levels.¹⁸

This is not a sign the drug “failed.” Obesity is a chronic condition driven by biological regulation of body weight. When the pharmacological signal that was suppressing appetite goes away, the underlying biology reasserts itself. The clinical implication is that most people will need to stay on the medication long-term to maintain their results, which is consistent with how we approach other chronic conditions like high blood pressure or high cholesterol.

Weight Loss Plateaus and Their Timing

Weight loss on semaglutide does not continue indefinitely. In a study that analyzed when patients hit a sustained plateau, the leveling off happened at around 53 weeks, with about 16% total weight loss at that point.¹⁹ A continuation trial found that in people who stayed on semaglutide beyond an initial 20-week run-in, weight loss continued until roughly weeks 60 to 68, ultimately reaching about 17.4% total. Those switched to placebo at week 20, by contrast, gradually regained.²⁰

Plateaus are a normal part of the pharmacology, not a sign that the drug has stopped working. The dose-response relationship with semaglutide is nonlinear: the biggest incremental effect comes with the initial doses, and each step up adds somewhat less additional weight loss than the one before.²¹ At some point the body reaches a new equilibrium where the appetite suppression and any metabolic effects balance out against the reduced energy expenditure that comes with a smaller body. This is when the drug shifts from weight-loss mode to weight-maintenance mode.

Reduced Dosing for Maintenance

Given the high cost of semaglutide and the reality that most people need it indefinitely, researchers have started asking whether a full 2.4 mg weekly dose is necessary once someone has reached their weight-loss plateau. The early evidence is encouraging. Modeling studies found that switching from weekly dosing to every two weeks maintained roughly 75% of the weight loss. If the less frequent doses were also slightly increased in size, the models predicted that essentially all of the weight loss could be preserved.²² A related analysis combining real-world and simulated data found that the majority of weight loss persisted even when patients waited two, three, or potentially four weeks between doses.²³

These are not yet guideline-endorsed protocols, and the large randomized trials needed to confirm them have not been completed. But the pharmacokinetic logic makes sense: semaglutide has a long half-life (about a week), meaning it stays in the body well past the seven-day dosing interval. Stretching that interval during maintenance, when the body’s new set point has already been established, is a different proposition from stretching it during the weight-loss phase when maximum receptor activation matters more.

A case report involving oral semaglutide illustrates the risks of underdosing during maintenance without careful monitoring. When a patient was dropped from 14 mg to 7 mg daily, weight regain followed. Re-increasing to 14 mg reversed the regain and maintained weight for a year afterward.²⁴ The takeaway is that dose reduction during maintenance can work, but it is not a set-and-forget strategy: weight should be tracked and the dose adjusted back up if regain begins.

What Happens If You Miss Doses or Need to Restart

Supply disruptions and insurance changes have been common with semaglutide, and gaps in treatment raise practical questions. A lapse of three or more weeks on the injectable (meaning three or more missed weekly doses) generally warrants restarting at a lower dose rather than jumping back to where you left off. The specific re-entry dose depends on how long you were off the drug, what dose you were previously tolerating, and how your GI system handled it last time.²⁵ Going back to the full 2.4 mg dose after a multi-week gap risks significant nausea and vomiting because the body’s tolerance to the GI effects wanes during the break.

If you miss just one dose (say, you are a day or two late), the standard guidance is to take it as soon as you remember, as long as the next scheduled dose is at least two days away. If it is closer than that, skip the missed dose and resume the normal schedule. The long half-life provides a buffer, so a single missed dose does not cause an immediate loss of appetite control.

Body Composition and Muscle Loss

Any large weight loss involves losing some muscle along with fat, and semaglutide is no exception. In an exploratory analysis from STEP 1, total fat mass dropped by about 19% and visceral fat by about 27%, while lean body mass decreased by about 10%. The proportion of lean mass relative to total body mass actually increased, meaning the body’s overall composition improved even though some muscle was lost in absolute terms.²⁶

A dedicated body composition study (SEMALEAN) found that fat mass fell by about 18% at 12 months, while lean mass dropped initially (about 3 kg at month seven) and then stabilized for the remainder of the year.²⁷ A systematic review of trials found that the proportion of weight lost as lean mass ranged from nearly zero to about 40% across studies, with the lean mass proportion relative to total body mass consistently going up, not down.²⁸

The practical advice most obesity specialists give is to pair semaglutide with resistance training and adequate protein intake to limit muscle loss. This is not unique to semaglutide; the same applies to bariatric surgery or any caloric-deficit weight loss approach. If you lose 15% of your body weight through any means, you will lose some lean tissue unless you actively work to preserve it.

Cardiovascular Benefits

Semaglutide’s effects go beyond the scale. In patients with type 2 diabetes, semaglutide at lower doses (0.5 mg and 1 mg weekly, the diabetes doses) reduced the risk of major cardiovascular events compared with placebo. The composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke occurred in about 6.6% of semaglutide-treated patients versus about 8.9% on placebo, driven primarily by a reduction in nonfatal stroke.²⁹

A later trial (SELECT) extended this finding to people with existing cardiovascular disease who had overweight or obesity but did not have diabetes. At the 2.4 mg weight-management dose, semaglutide was superior to placebo in reducing cardiovascular death, nonfatal heart attack, and nonfatal stroke over a mean follow-up of about 40 months.³⁰ These results helped establish that the cardiovascular protection is not just a side effect of better blood sugar control; it occurs in people without diabetes who lose weight on the drug.

Dosing in Adolescents

Semaglutide 2.4 mg weekly has been studied in adolescents aged 12 and older with obesity. The dose and escalation schedule are the same as for adults. In a trial of 201 adolescents, semaglutide reduced BMI by about 16% over 68 weeks compared with a slight increase in the placebo group. About 73% of adolescents on semaglutide achieved at least 5% weight loss.³¹ Side effects mirrored adult patterns: GI symptoms were more common with semaglutide (62% versus 42% on placebo), were concentrated during dose escalation, and rarely led to discontinuation (about 5% in both groups).³² Cholelithiasis (gallstones) was observed in 4% of adolescents on semaglutide and none on placebo, a small but notable signal.

How Semaglutide Compares with Tirzepatide

Tirzepatide (Zepbound/Mounjaro) is the most direct comparator, and people researching semaglutide dosing inevitably wonder how the two stack up. A meta-analysis combining trial and real-world data found that tirzepatide produced about 4 kg more weight loss than semaglutide overall, with a larger advantage at higher tirzepatide doses (above 10 mg) and with longer treatment duration.³³ An indirect comparison from diabetes trials specifically showed that tirzepatide at 10 mg and 15 mg produced significantly more weight loss than semaglutide at 2 mg (the diabetes dose, not the 2.4 mg obesity dose), while tirzepatide at 5 mg was roughly equivalent.³⁴ Tirzepatide activates two gut hormone receptors (GLP-1 and GIP) rather than just GLP-1, which appears to explain the additional weight loss.

Higher Doses and Combination Therapies on the Horizon

The FDA has approved a higher-dose injectable semaglutide, reflecting the recognition that some patients could benefit from doses above 2.4 mg.³⁵ Meanwhile, the most closely watched development is the combination of semaglutide with cagrilintide, an amylin analogue that targets a different appetite-regulating pathway. In a trial, the combination produced about 20% weight loss at 68 weeks, compared with about 3% for placebo, and meaningfully outperformed semaglutide 2.4 mg alone.³⁶ A meta-analysis of earlier-phase trials confirmed the advantage, showing approximately 9 percentage points more weight loss with the combination than with semaglutide alone at 20 to 32 weeks.³⁷

Compounded and “Microdosed” Semaglutide

The shortage and high cost of branded semaglutide have driven interest in compounded versions and in the practice of “microdosing,” where people use subtherapeutic doses often obtained from compounding pharmacies. The safety concerns here are real. Compounded semaglutide does not go through the same regulatory scrutiny as the branded product, and dosing accuracy can vary between batches. Reports of side effects and dosing errors have emerged, along with risks from pen manipulation and medication sharing.³⁸ Using subtherapeutic doses also means you are unlikely to achieve the weight loss seen in trials, since the clinical evidence supports the full 2.4 mg dose as the effective target. If cost is the barrier, it is worth exploring manufacturer savings programs, insurance appeals, or discussing tirzepatide or other alternatives with your prescriber before turning to unregulated sources.